Cyclacel Pharmaceuticals, Inc. (CYCCP)
- Previous Close
8.00 - Open
7.90 - Bid --
- Ask --
- Day's Range
7.90 - 10.00 - 52 Week Range
5.25 - 22.20 - Volume
5,769 - Avg. Volume
1,511 - Market Cap (intraday)
19.015M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-2.05 - Earnings Date --
- Forward Dividend & Yield 0.60 (6.00%)
- Ex-Dividend Date Jan 19, 2024
- 1y Target Est
--
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
www.cyclacel.comRecent News: CYCCP
Performance Overview: CYCCP
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYCCP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYCCP
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-86.33%
Return on Equity (ttm)
-272.63%
Revenue (ttm)
420k
Net Income Avi to Common (ttm)
-22.76M
Diluted EPS (ttm)
-2.05
Balance Sheet and Cash Flow
Total Cash (mrq)
3.38M
Total Debt/Equity (mrq)
6.10%
Levered Free Cash Flow (ttm)
-11.76M
Company Insights: CYCCP
CYCCP does not have Company Insights